Medicare AdvantagePrior AuthMedium impact
MA08.085i, Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Jan 1, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage updated the medical necessity criteria for Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®), a specialty pharmacy medication. This affects prior authorization and coverage requirements for this specific drug used in cancer treatment.
Action Required
Immediately: Review updated medical necessity criteria for Rylaze® (Asparaginase Erwinia Chrysanthemi) prior authorizations. Billing team and providers must ensure all prior authorization requests for this specialty oncology medication include documentation that meets the new medical necessity requirements. Update prior auth checklists and provider templates accordingly.